Experienced in Ewing Sarcoma

Dr. Ignacio Garrido-Laguna

Oncology | Hematology
University Of Utah Adult Services
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (1668.1 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Ewing Sarcoma
University Of Utah Adult Services
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (1668.1 mi)
OverviewInsuranceLocationsClinical Research

Overview

Ignacio Garrido-Laguna is an Oncologist and a Hematologist in Salt Lake City, Utah. Dr. Garrido-Laguna and is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatoblastoma, and Pancreatectomy. Dr. Garrido-Laguna is currently accepting new patients.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in UT
Hospital Affiliations
University Of Utah Hospital And Clinics
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  BridgeSpan
  •  SelectHealth
  •  Regence
  •  UnitedHealthcare

Locations

UNIVERSITY OF UTAH ADULT SERVICES
1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel, SM-88, mFOLFIRINOX
Study Phase: Phase 3
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Drug
Study Drugs: TP-1454 Alone, TP-1454 Combination Therapy
Study Phase: Phase 1
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2024
Intervention Type: Other
A Phase 1b Trial of a Combination of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
A Phase 1b Trial of a Combination of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: MEK162, mFOLFIRI
Study Phase: Phase 1
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)
Enrollment Status: Active_not_recruiting
Publish Date: May 17, 2024
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Leucovorin calcium, Liposomal irinotecan, Rucaparib
Study Phase: Phase 1/Phase 2
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Phase: Phase 1
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: October 04, 2023
Intervention Type: Drug
Study Drugs: TTX-030, Pembrolizumab, Docetaxel, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: April 04, 2023
Intervention Type: Drug
Study Drugs: ABC294640, Hydroxychloroquine Sulfate
Study Phase: Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
Enrollment Status: Terminated
Publish Date: May 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: April 28, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 20 Less Clinical Trials

112 Total Publications

Gemcitabine-induced myositis in a patient with pancreatic cancer.
Gemcitabine-induced myositis in a patient with pancreatic cancer.
Journal: BMJ case reports
Published: January 22, 2025
Similar Doctors
Distinguished in Ewing Sarcoma
Dr. Anna W. Chalmers
Hematology Oncology | Hematology | Oncology
Distinguished in Ewing Sarcoma
Dr. Anna W. Chalmers
Hematology Oncology | Hematology | Oncology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
801-581-8793
Experience:
15+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anna Chalmers is a Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Chalmers has been practicing medicine for over 15 years and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Liposarcoma, and Rhabdomyosarcoma Embryonal. Dr. Chalmers is currently accepting new patients.

Advanced in Ewing Sarcoma
Dr. Phillip E. Barnette
Pediatric Hematology Oncology | Hematology | Oncology
Advanced in Ewing Sarcoma
Dr. Phillip E. Barnette
Pediatric Hematology Oncology | Hematology | Oncology
100 Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.2 mi)
801-662-4700
Languages Spoken:
English

Phillip Barnette is a Pediatric Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Barnette and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Burkitt Lymphoma, Acute Lymphoblastic Leukemia (ALL), Langerhans Cell Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

Advanced in Ewing Sarcoma
Dr. Joan D. Miles
Surgical Oncology | Oncology | Orthopedics
Advanced in Ewing Sarcoma
Dr. Joan D. Miles
Surgical Oncology | Oncology | Orthopedics

Ihc Health Services Inc

5169 S Cottonwood St, Suite 430, 
Murray, UT 
 (8.3 mi)
801-507-3475
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Joan Miles is a Surgical Oncologist and an Oncologist in Murray, Utah. Dr. Miles and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Bone Tumor, Rhabdomyosarcoma Embryonal, Myxoid Liposarcoma, Fibrosarcoma, and Knee Replacement.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile